drugset / Trial / NCT03010579

Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation

NCT03010579

Phase 4 Unknown 70 enrolled Peking University
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an randomized trial to evaluate the potential benefit of erythropoietin in the treatment of anemia in patients with lymphoma after autologous hematopoietic stem cell transplantation.

Timeline

Start
2016-10
Primary completion
2017-12
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 10000 iu Subcutaneous
Comparator B12 Other / unclassified Oral
Comparator Ferrous Sulfate Diagnostic / imaging agent Oral
Comparator folic acid Other / unclassified Oral

Indications